Ankylosing Spondylitis
Conditions
Brief summary
Primary objective: \- to evaluate the efficacy of Sarilumab in participants with Ankylosing Spondylitis (AS) using the assessment in AS working group criteria (ASAS) 20% response criteria (ASAS20) Secondary objectives: * to demonstrate that Sarilumab was effective on: * assessment of higher level of response \[ASAS 40% response criteria (ASAS40)\] * partial remission * disease activity * range of motion * Magnetic Resonance Imaging (MRI) of the spine * to assess the safety and tolerability of Sarilumab in participants with AS as well as the pharmacokinetic profile of Sarilumab in participants with AS
Detailed description
The duration of participation in this study for each participant was approximately 22 weeks; including up to 4 weeks screening period, 12-weeks double-blind treatment period and 6-weeks safety follow-up period.
Interventions
DRUGSarilumab
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
DRUGPlacebo
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Sponsors
Regeneron Pharmaceuticals
Sanofi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of AS according to the New York modified criteria * Participants must had an adequate trial of at least 2 different Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) taken for at least 2 weeks in each case and, on a stable dose for ≥2 weeks or be intolerant to NSAIDs * Participants must had active AS for ≥3 months before screening and active disease must be present at screening and at baseline; Active AS being defined by: * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥4 (Numerical Rating Scale 0-10) * Total back pain score ≥4 (Numerical Rating Scale 0-10) Participants treated with corticosteroid must be on a stable dose for ≥2 weeks prior to baseline Participants treated with the Disease Modifying Anti-Rheumatic Drugs (DMARDs) hydroxychloroquine, sulfasalazine and methotrexate (MTX) must be on stable dose ≥12 weeks prior to baseline
Exclusion criteria
* \<18 years old or ≥75 years old * Complete fusion of the spine * Past history of non response to any anti-Tumor Necrosis Factors (TNFs) treatment or non response to any other biological treatment for AS * Any past or current treatment with anti-TNF's or any biological agent within 3 months prior to screening * Treatment with DMARDs except for hydroxychloroquine, sulfasalazine and MTX * MTX \>25 mg/week * hydroxychloroquine \>400 mg/day * Sulfasalazine \>3 g/day * Treatment with oral prednisone or equivalent corticosteroids \>10 mg/day within 6 weeks prior to screening * Use of intramuscular or intra-articular corticosteroids within the last 4 weeks before screening * Previous treatment with cyclosporine, azathioprine The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | Baseline to Week 12 (Last Observation Carried Forward [LOCF]) | Clinical response to treatment for ASAS20 was assessed according to ASAS20 criteria. Treatment response for ASAS20 was defined as an improvement by a decrease of ≥20% and ≥1unit on a 0 (no pain) - 10 (most severe pain) numerical rating scale (NRS) in at least 3 of the 4 ASAS improvement criteria (ASAS-IC) domains: assessment of physical function (measured by Bath Ankylosing Spondylitis Functional Index \[BASFI\]), back pain (0-10 NRS), participant global assessment (0-10 NRS) and inflammation (measured as the mean of the last 2 Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] questions) and no worsening (increase in score) of ≥20% and ≥1 unit on a 0-10 NRS in the remaining 4th domain. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | Baseline to Week 12 (LOCF) | Participants were classified as having achieved ASAS partial remission if they had a value ≤ 2 units on a 0 -10 NRS in each of the 4 domains: (participant global assessment, back pain, physical function and inflammation) of the ASAS-IC. |
| Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | Baseline, Week 12 (LOCF) | ASDAS consists of five components: (Total back pain assessed by BASDAI question 2 on a 0 \[no pain\] - 10 \[most severe pain\] NRS, participant global of disease activity on a 0 \[none\] - 10 \[severe\] NRS, peripheral pain/swelling assessed by BASDAI question 3 on a 0 \[none\] - 10 \[most severe pain\] NRS, duration of morning stiffness assessed by BASDAI question 6 on a NRS from 0 \[0 hour\] - 10 \[2 or more hours\] and hs-CRP in mg/L). ASDAS score was calculated as follows: 0.121 x total back pain + 0.110 x participant global of disease activity + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(CRP + 1). The scores were categorized as: inactive disease (\< 1.3), moderate (1.3 - \< 2.1), high (2.1 - 3.5) and very high disease activity (\> 3.5). |
| Change From Baseline in BASDAI Score at Week 12 | Baseline, Week 12 (LOCF) | BASDAI comprises of a 0 (no pain) -10 (very severe pain) NRS, used to answer 6 questions (Q) related to symptoms of AS (fatigue/tiredness, neck, back or hip pain, pain / swelling in joints, discomfort in tender areas, morning stiffness duration and morning stiffness severity). The BASDAI total score was calculated by computing the mean of Q5 and Q6 and adding it to the sum of Q1 to Q4. This score was then divided by 5. BASDAI total score=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The total BASDAI score ranges from 0=none to 10=severe, where lower score indicated less disease activity. |
| Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | Baseline, Week 12 (LOCF) | The range of motion was measured by the BASMI (11-point scale) including chest expansion in cm. It composed of 5 clinical measurements associated with a score: tragus to wall distance, modified schober's test, lateral spinal flexion, intermalleolar distance and cervical rotation. BASMI score was calculated by dividing the total of the score by 5, and the score ranges from 0-10. Higher BASMI score indicates more severe limitation of movement. |
| Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | Baseline, Week 12 | ASspiMRI-a scoring system was used on all MRIs to score the level of the disease. MRIs were obtained using 1.0 or 1.5 Tesla scanners and phased array coils. Sagittal images of the upper (C2 to T10) and lower (T8 to S1) spine were used using both T1 weighted spin echo and fat saturated Short Tau Inversion Recovery (STIR) sequences. Each vertebral body unit was given an activity score based on the amount of bone marrow edema or erosion. Both T1 and STIR sequences were analyzed for change. Total spine ASspiMRI-a score in the Berlin modification range from 0 to 69 with higher scores indicating higher disease activity. A negative value in total spine ASspiMRI-a score change from baseline indicates an improvement from baseline. The higher the negative value the higher the reduction of inflammation. |
| Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | Baseline to Week 12 (LOCF) | Clinical response to treatment for ASAS40 was assessed according to ASAS40 criteria. Treatment response for ASAS40 was defined as an improvement by a decrease of ≥40% and ≥2 units on a 0 (no pain)-10 (most severe pain) NRS in at least 3 of the 4 ASAS-IC domains (participant global assessment, back pain, physical function and inflammation) and no worsening (increase in score) at all in the remaining 4th domain. |
| Change From Baseline in Chest Expansion at Week 12 | Baseline, Week 12 (LOCF) | The difference between maximal inspiration and expiration to the nearest 0.1 cm was recorded. The best of 2 tries were recorded. |
| Change From Baseline in Swollen Joint Index at Week 12 | Baseline, Week 12 (LOCF) | 44 swollen joints were examined including sternal, clavicular, elbow, shoulder, wrist, knee, metacarpophalangian, interphalangian, metatarpophalangian and metatarsophalangeal joints. |
| Change From Baseline in Hs-CRP at Week 12 | Baseline, Week 12 (LOCF) | Participant's blood samples were collected at screening, baseline before dosing and at every visit to evaluate the level of hs-CRP. The hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation. |
| Change From Baseline in ASAS Individual Components at Week 12 | Baseline, Week 12 (LOCF) | ASAS consists of 4 individual components: Participant global assessment to assess the disease activity over the last week on a 0 (no pain) - 10 (severe pain) NRS; back pain which consist of the mean of the nocturnal back pain and the total back pain at every visit on a 0 (no pain) - 10 (most severe pain) NRS; inflammation measured as the mean of the last 2 BASDAI questions (intensity and duration of morning stiffness) and physical function measured as mean of 10 scores of BASFI at every visit on 0 (easy) -10 (impossible) NRS. Lower score corresponds to a better functioning. |
| Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | Baseline to Week 12 (LOCF) | ASAS 5/6 responder had an improvement of 20% in 5 of 6 domains (physical function, back pain, participant global assessment, inflammation, spinal mobility and acute phase reactants) of ASAS-IC without deterioration in the 6th domain. Spinal mobility was assessed by the mean of the 5 BASMI scores on the 11-point scale (score ranges from 0-10) and the hs-CRP for the acute phase reactant. |
Countries
Australia, Austria, Belgium, Canada, Czechia, France, Germany, Hungary, Lithuania, Netherlands, Poland, Spain, Turkey (Türkiye), United States
Participant flow
Recruitment details
The study was conducted at 68 centers in Europe, Canada and the United States. A total of 563 participants were screened between 04 February 2010 and 24 February 2011. Of 563 participants, 301 were randomized and 300 were treated.
Pre-assignment details
Participants were randomized in 1:1:1:1:1:1 ratio for Placebo and Sarilumab (100 mg weekly \[qw\]; 150 mg qw; 100 mg every other week \[q2w\]; 150 mg q2w and 200 mg q2w) with screening high-sensitivity C-Reactive Protein (hs-CRP) (≤1.5 mg/L or \>1.5 mg/L) and region as stratification factors.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Placebo (for sarilumab) qw for 12 weeks. | 50 |
| Sarilumab 100 mg q2w Sarilumab 100 mg SC injection alternating with placebo q2w for 12 weeks. | 49 |
| Sarilumab 150 mg q2w Sarilumab 150 mg SC injection alternating with placebo q2w for 12 weeks. | 50 |
| Sarilumab 100 mg qw Sarilumab 100 mg SC injection qw for 12 weeks. | 52 |
| Sarilumab 200 mg q2w Sarilumab 200 mg SC injection alternating with placebo q2w for 12 weeks. | 50 |
| Sarilumab 150 mg qw Sarilumab 150 mg SC injection qw for 12 weeks. | 50 |
| Total | 301 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 5 | 5 | 2 | 6 |
| Overall Study | Lack of Efficacy | 2 | 3 | 4 | 2 | 1 | 1 |
| Overall Study | Other than specified above | 2 | 1 | 1 | 1 | 0 | 1 |
| Overall Study | Randomized but not treated | 0 | 0 | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Placebo | Sarilumab 100 mg q2w | Sarilumab 150 mg q2w | Sarilumab 100 mg qw | Sarilumab 200 mg q2w | Sarilumab 150 mg qw | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 40.3 years STANDARD_DEVIATION 11.7 | 42.4 years STANDARD_DEVIATION 10.8 | 43.0 years STANDARD_DEVIATION 11.3 | 40.4 years STANDARD_DEVIATION 11.5 | 37.2 years STANDARD_DEVIATION 10.4 | 41.1 years STANDARD_DEVIATION 11.1 | 40.7 years STANDARD_DEVIATION 11.2 |
| Sex: Female, Male Female | 12 Participants | 19 Participants | 16 Participants | 15 Participants | 10 Participants | 11 Participants | 83 Participants |
| Sex: Female, Male Male | 38 Participants | 30 Participants | 34 Participants | 37 Participants | 40 Participants | 39 Participants | 218 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 7 / 50 | 18 / 49 | 23 / 51 | 22 / 52 | 19 / 49 | 22 / 49 |
| serious Total, serious adverse events | 0 / 50 | 1 / 49 | 4 / 51 | 1 / 52 | 0 / 49 | 1 / 49 |
Outcome results
Primary
Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12
Clinical response to treatment for ASAS20 was assessed according to ASAS20 criteria. Treatment response for ASAS20 was defined as an improvement by a decrease of ≥20% and ≥1unit on a 0 (no pain) - 10 (most severe pain) numerical rating scale (NRS) in at least 3 of the 4 ASAS improvement criteria (ASAS-IC) domains: assessment of physical function (measured by Bath Ankylosing Spondylitis Functional Index \[BASFI\]), back pain (0-10 NRS), participant global assessment (0-10 NRS) and inflammation (measured as the mean of the last 2 Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] questions) and no worsening (increase in score) of ≥20% and ≥1 unit on a 0-10 NRS in the remaining 4th domain.
Time frame: Baseline to Week 12 (Last Observation Carried Forward [LOCF])
Population: Intent-to-treat (ITT) population included all randomized participants. Missing data was imputed using LOCF.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 24.0 percentage of participants |
| Sarilumab 100 mg q2w | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 24.5 percentage of participants |
| Sarilumab 150 mg q2w | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 30.0 percentage of participants |
| Sarilumab 100 mg qw | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 19.2 percentage of participants |
| Sarilumab 200 mg q2w | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 30.0 percentage of participants |
| Sarilumab 150 mg qw | Percentage of Participants Who Achieved 20% Response According to the Assessment in Ankylosing Spondylitis (AS) Working Group Criteria for Response (ASAS20) at Week 12 | 38.0 percentage of participants |
Comparison: Sarilumab group was compared to placebo group. Analysis was performed using two-sided Cochran-Mantel-Haenszel test. Pairwise comparisons of the response rates between each dose of sarilumab and placebo were derived.p-value: 0.96695% CI: [0.4, 2.5]Cochran-Mantel-Haenszel
p-value: 0.46795% CI: [0.6, 3.5]Cochran-Mantel-Haenszel
p-value: 0.55995% CI: [0.3, 1.9]Cochran-Mantel-Haenszel
p-value: 0.49695% CI: [0.6, 3.4]Cochran-Mantel-Haenszel
p-value: 0.14395% CI: [0.8, 4.2]Cochran-Mantel-Haenszel
Secondary
Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12
ASDAS consists of five components: (Total back pain assessed by BASDAI question 2 on a 0 \[no pain\] - 10 \[most severe pain\] NRS, participant global of disease activity on a 0 \[none\] - 10 \[severe\] NRS, peripheral pain/swelling assessed by BASDAI question 3 on a 0 \[none\] - 10 \[most severe pain\] NRS, duration of morning stiffness assessed by BASDAI question 6 on a NRS from 0 \[0 hour\] - 10 \[2 or more hours\] and hs-CRP in mg/L). ASDAS score was calculated as follows: 0.121 x total back pain + 0.110 x participant global of disease activity + 0.073 x peripheral pain/swelling + 0.058 x duration of morning stiffness + 0.579 x ln(CRP + 1). The scores were categorized as: inactive disease (\< 1.3), moderate (1.3 - \< 2.1), high (2.1 - 3.5) and very high disease activity (\> 3.5).
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with ASDAS score assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -0.4 units on a scale | Standard Deviation 0.7 |
| Sarilumab 100 mg q2w | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -0.5 units on a scale | Standard Deviation 0.9 |
| Sarilumab 150 mg q2w | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -0.8 units on a scale | Standard Deviation 1.2 |
| Sarilumab 100 mg qw | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -1.1 units on a scale | Standard Deviation 0.8 |
| Sarilumab 200 mg q2w | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -1.2 units on a scale | Standard Deviation 0.9 |
| Sarilumab 150 mg qw | Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12 | -1.6 units on a scale | Standard Deviation 0.9 |
Secondary
Change From Baseline in ASAS Individual Components at Week 12
ASAS consists of 4 individual components: Participant global assessment to assess the disease activity over the last week on a 0 (no pain) - 10 (severe pain) NRS; back pain which consist of the mean of the nocturnal back pain and the total back pain at every visit on a 0 (no pain) - 10 (most severe pain) NRS; inflammation measured as the mean of the last 2 BASDAI questions (intensity and duration of morning stiffness) and physical function measured as mean of 10 scores of BASFI at every visit on 0 (easy) -10 (impossible) NRS. Lower score corresponds to a better functioning.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with ASAS assessment at specified time-points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -0.8 units on a scale | Standard Deviation 1.8 |
| Placebo | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -1.4 units on a scale | Standard Deviation 1.8 |
| Placebo | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -1.0 units on a scale | Standard Deviation 1.9 |
| Placebo | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -0.6 units on a scale | Standard Deviation 1.2 |
| Sarilumab 100 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -0.5 units on a scale | Standard Deviation 1.7 |
| Sarilumab 100 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -1.3 units on a scale | Standard Deviation 2.2 |
| Sarilumab 100 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -0.8 units on a scale | Standard Deviation 2 |
| Sarilumab 100 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -1.1 units on a scale | Standard Deviation 2.3 |
| Sarilumab 150 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -1.2 units on a scale | Standard Deviation 2.4 |
| Sarilumab 150 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -0.8 units on a scale | Standard Deviation 2.3 |
| Sarilumab 150 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -0.4 units on a scale | Standard Deviation 2 |
| Sarilumab 150 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -1.1 units on a scale | Standard Deviation 2 |
| Sarilumab 100 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -0.5 units on a scale | Standard Deviation 1.8 |
| Sarilumab 100 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -0.4 units on a scale | Standard Deviation 2.2 |
| Sarilumab 100 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -0.1 units on a scale | Standard Deviation 1.4 |
| Sarilumab 100 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -0.7 units on a scale | Standard Deviation 2.1 |
| Sarilumab 200 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -1.0 units on a scale | Standard Deviation 1.9 |
| Sarilumab 200 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -0.9 units on a scale | Standard Deviation 2.2 |
| Sarilumab 200 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -0.9 units on a scale | Standard Deviation 2.2 |
| Sarilumab 200 mg q2w | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -0.6 units on a scale | Standard Deviation 1.9 |
| Sarilumab 150 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Physical function | -1.1 units on a scale | Standard Deviation 1.9 |
| Sarilumab 150 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Participant global assessment | -1.6 units on a scale | Standard Deviation 2 |
| Sarilumab 150 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Back pain | -1.6 units on a scale | Standard Deviation 2.1 |
| Sarilumab 150 mg qw | Change From Baseline in ASAS Individual Components at Week 12 | Inflammation | -1.8 units on a scale | Standard Deviation 2.3 |
Secondary
Change From Baseline in BASDAI Score at Week 12
BASDAI comprises of a 0 (no pain) -10 (very severe pain) NRS, used to answer 6 questions (Q) related to symptoms of AS (fatigue/tiredness, neck, back or hip pain, pain / swelling in joints, discomfort in tender areas, morning stiffness duration and morning stiffness severity). The BASDAI total score was calculated by computing the mean of Q5 and Q6 and adding it to the sum of Q1 to Q4. This score was then divided by 5. BASDAI total score=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The total BASDAI score ranges from 0=none to 10=severe, where lower score indicated less disease activity.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with BASDAI score assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in BASDAI Score at Week 12 | -0.9 units on a scale | Standard Deviation 1.7 |
| Sarilumab 100 mg q2w | Change From Baseline in BASDAI Score at Week 12 | -0.8 units on a scale | Standard Deviation 1.9 |
| Sarilumab 150 mg q2w | Change From Baseline in BASDAI Score at Week 12 | -1.1 units on a scale | Standard Deviation 2 |
| Sarilumab 100 mg qw | Change From Baseline in BASDAI Score at Week 12 | -0.4 units on a scale | Standard Deviation 1.4 |
| Sarilumab 200 mg q2w | Change From Baseline in BASDAI Score at Week 12 | -0.9 units on a scale | Standard Deviation 1.8 |
| Sarilumab 150 mg qw | Change From Baseline in BASDAI Score at Week 12 | -1.2 units on a scale | Standard Deviation 1.8 |
Secondary
Change From Baseline in Chest Expansion at Week 12
The difference between maximal inspiration and expiration to the nearest 0.1 cm was recorded. The best of 2 tries were recorded.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with chest expansion assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Chest Expansion at Week 12 | 0.2 cm | Standard Deviation 1 |
| Sarilumab 100 mg q2w | Change From Baseline in Chest Expansion at Week 12 | 0.2 cm | Standard Deviation 1.2 |
| Sarilumab 150 mg q2w | Change From Baseline in Chest Expansion at Week 12 | 0.0 cm | Standard Deviation 1.2 |
| Sarilumab 100 mg qw | Change From Baseline in Chest Expansion at Week 12 | -0.1 cm | Standard Deviation 0.9 |
| Sarilumab 200 mg q2w | Change From Baseline in Chest Expansion at Week 12 | 0.1 cm | Standard Deviation 1.3 |
| Sarilumab 150 mg qw | Change From Baseline in Chest Expansion at Week 12 | 0.3 cm | Standard Deviation 1.3 |
Secondary
Change From Baseline in Hs-CRP at Week 12
Participant's blood samples were collected at screening, baseline before dosing and at every visit to evaluate the level of hs-CRP. The hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with Hs-CRP assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Hs-CRP at Week 12 | -3.7 mg/dL | Standard Deviation 19.1 |
| Sarilumab 100 mg q2w | Change From Baseline in Hs-CRP at Week 12 | -1.2 mg/dL | Standard Deviation 17.9 |
| Sarilumab 150 mg q2w | Change From Baseline in Hs-CRP at Week 12 | -5.8 mg/dL | Standard Deviation 27.6 |
| Sarilumab 100 mg qw | Change From Baseline in Hs-CRP at Week 12 | -13.5 mg/dL | Standard Deviation 20.3 |
| Sarilumab 200 mg q2w | Change From Baseline in Hs-CRP at Week 12 | -11.5 mg/dL | Standard Deviation 17.5 |
| Sarilumab 150 mg qw | Change From Baseline in Hs-CRP at Week 12 | -14.3 mg/dL | Standard Deviation 15.3 |
Secondary
Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12
ASspiMRI-a scoring system was used on all MRIs to score the level of the disease. MRIs were obtained using 1.0 or 1.5 Tesla scanners and phased array coils. Sagittal images of the upper (C2 to T10) and lower (T8 to S1) spine were used using both T1 weighted spin echo and fat saturated Short Tau Inversion Recovery (STIR) sequences. Each vertebral body unit was given an activity score based on the amount of bone marrow edema or erosion. Both T1 and STIR sequences were analyzed for change. Total spine ASspiMRI-a score in the Berlin modification range from 0 to 69 with higher scores indicating higher disease activity. A negative value in total spine ASspiMRI-a score change from baseline indicates an improvement from baseline. The higher the negative value the higher the reduction of inflammation.
Time frame: Baseline, Week 12
Population: ITT population. Number of participants analyzed = participants with ASspiMRI-a assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | -0.5 units on a scale | Standard Deviation 2.2 |
| Sarilumab 100 mg q2w | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | -0.5 units on a scale | Standard Deviation 1.8 |
| Sarilumab 150 mg q2w | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | -0.1 units on a scale | Standard Deviation 3.4 |
| Sarilumab 100 mg qw | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | 0.1 units on a scale | Standard Deviation 2.4 |
| Sarilumab 200 mg q2w | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | -0.3 units on a scale | Standard Deviation 3.3 |
| Sarilumab 150 mg qw | Change From Baseline in Magnetic Resonance Imaging (MRI) Score of the Spine Assessed by the Berlin Modification of the AS Spine MRI-active (ASspiMRI-a) Score at Week 12 | 0.3 units on a scale | Standard Deviation 3.3 |
Secondary
Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12
The range of motion was measured by the BASMI (11-point scale) including chest expansion in cm. It composed of 5 clinical measurements associated with a score: tragus to wall distance, modified schober's test, lateral spinal flexion, intermalleolar distance and cervical rotation. BASMI score was calculated by dividing the total of the score by 5, and the score ranges from 0-10. Higher BASMI score indicates more severe limitation of movement.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed=participants with BASMI score assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.2 units on a scale | Standard Deviation 0.8 |
| Sarilumab 100 mg q2w | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.2 units on a scale | Standard Deviation 0.9 |
| Sarilumab 150 mg q2w | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.2 units on a scale | Standard Deviation 0.8 |
| Sarilumab 100 mg qw | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.4 units on a scale | Standard Deviation 0.9 |
| Sarilumab 200 mg q2w | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.1 units on a scale | Standard Deviation 0.8 |
| Sarilumab 150 mg qw | Change From Baseline in Range of Motion Assessed by the Bath AS Metrology Index (BASMI) at Week 12 | -0.2 units on a scale | Standard Deviation 0.7 |
Secondary
Change From Baseline in Swollen Joint Index at Week 12
44 swollen joints were examined including sternal, clavicular, elbow, shoulder, wrist, knee, metacarpophalangian, interphalangian, metatarpophalangian and metatarsophalangeal joints.
Time frame: Baseline, Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF. Number of participants analyzed = participants with swollen joint count assessment at specified time-points.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Swollen Joint Index at Week 12 | -0.4 Joints | Standard Deviation 1.1 |
| Sarilumab 100 mg q2w | Change From Baseline in Swollen Joint Index at Week 12 | -0.8 Joints | Standard Deviation 3.1 |
| Sarilumab 150 mg q2w | Change From Baseline in Swollen Joint Index at Week 12 | -0.3 Joints | Standard Deviation 1.9 |
| Sarilumab 100 mg qw | Change From Baseline in Swollen Joint Index at Week 12 | -0.3 Joints | Standard Deviation 2.4 |
| Sarilumab 200 mg q2w | Change From Baseline in Swollen Joint Index at Week 12 | -0.4 Joints | Standard Deviation 1.6 |
| Sarilumab 150 mg qw | Change From Baseline in Swollen Joint Index at Week 12 | -0.2 Joints | Standard Deviation 7.3 |
Secondary
Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12
Clinical response to treatment for ASAS40 was assessed according to ASAS40 criteria. Treatment response for ASAS40 was defined as an improvement by a decrease of ≥40% and ≥2 units on a 0 (no pain)-10 (most severe pain) NRS in at least 3 of the 4 ASAS-IC domains (participant global assessment, back pain, physical function and inflammation) and no worsening (increase in score) at all in the remaining 4th domain.
Time frame: Baseline to Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 8.0 percentage of participants |
| Sarilumab 100 mg q2w | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 14.3 percentage of participants |
| Sarilumab 150 mg q2w | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 16.0 percentage of participants |
| Sarilumab 100 mg qw | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 5.8 percentage of participants |
| Sarilumab 200 mg q2w | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 18.0 percentage of participants |
| Sarilumab 150 mg qw | Percentage of Participants Who Achieved 40% Response According to the Assessment in AS Working Group Criteria for Response (ASAS40) at Week 12 | 20.0 percentage of participants |
Secondary
Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12
ASAS 5/6 responder had an improvement of 20% in 5 of 6 domains (physical function, back pain, participant global assessment, inflammation, spinal mobility and acute phase reactants) of ASAS-IC without deterioration in the 6th domain. Spinal mobility was assessed by the mean of the 5 BASMI scores on the 11-point scale (score ranges from 0-10) and the hs-CRP for the acute phase reactant.
Time frame: Baseline to Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 6.0 percentage of participants |
| Sarilumab 100 mg q2w | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 12.2 percentage of participants |
| Sarilumab 150 mg q2w | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 10.0 percentage of participants |
| Sarilumab 100 mg qw | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 13.5 percentage of participants |
| Sarilumab 200 mg q2w | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 14.0 percentage of participants |
| Sarilumab 150 mg qw | Percentage of Participants Who Achieved ASAS 5/6 Improvement Criteria at Week 12 | 32.0 percentage of participants |
Secondary
Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12
Participants were classified as having achieved ASAS partial remission if they had a value ≤ 2 units on a 0 -10 NRS in each of the 4 domains: (participant global assessment, back pain, physical function and inflammation) of the ASAS-IC.
Time frame: Baseline to Week 12 (LOCF)
Population: ITT population. Missing data was imputed using LOCF.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 2.0 percentage of participants |
| Sarilumab 100 mg q2w | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 8.2 percentage of participants |
| Sarilumab 150 mg q2w | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 2.0 percentage of participants |
| Sarilumab 100 mg qw | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 1.9 percentage of participants |
| Sarilumab 200 mg q2w | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 2.0 percentage of participants |
| Sarilumab 150 mg qw | Percentage of Participants Who Achieved Partial Remission According to the Assessment in AS Working Group Criteria for Response (ASAS) at Week 12 | 8.0 percentage of participants |